Cargando…
Ease of Use, Preference, and Safety of the Recombinant Human Growth Hormone Disposable Pen Compared with the Reusable Device: A Multicenter, Single-Arm, Open-Label, Switch-Over, Prospective, Phase IV Trial
PURPOSE: To assess the usability and safety of the disposable pen compared to those of reusable devices in patients receiving recombinant human growth hormone (rhGH) treatment. PATIENTS AND METHODS: This study was a multicenter, single-arm, open-label, switch-over, prospective, Phase IV trial. After...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6929929/ https://www.ncbi.nlm.nih.gov/pubmed/31908426 http://dx.doi.org/10.2147/PPA.S229536 |
_version_ | 1783482795978391552 |
---|---|
author | Lee, Ji-Eun Kim, Se Young Yoo, Jae-Ho Hwang, Il Tae Lim, Jung Sub Yi, Kyung Hee Rhie, Young-Jun Lee, Gyung Min Nam, Hyo-Kyoung Chae, Hyun Wook Kim, Eun Young Cheon, Chong Kun Lee, Jieun Shim, Young Suk Lee, YuJin Kim, Eun Young Hwang, Jin Soon |
author_facet | Lee, Ji-Eun Kim, Se Young Yoo, Jae-Ho Hwang, Il Tae Lim, Jung Sub Yi, Kyung Hee Rhie, Young-Jun Lee, Gyung Min Nam, Hyo-Kyoung Chae, Hyun Wook Kim, Eun Young Cheon, Chong Kun Lee, Jieun Shim, Young Suk Lee, YuJin Kim, Eun Young Hwang, Jin Soon |
author_sort | Lee, Ji-Eun |
collection | PubMed |
description | PURPOSE: To assess the usability and safety of the disposable pen compared to those of reusable devices in patients receiving recombinant human growth hormone (rhGH) treatment. PATIENTS AND METHODS: This study was a multicenter, single-arm, open-label, switch-over, prospective, Phase IV trial. After screening, eligible patients who were previously treated with rhGH using a reusable device were enrolled to receive treatment with the disposable pen for 8 weeks. The ease of use, preference, and tolerability of the disposable pen compared to those of the reusable device were assessed by the subjects and/or their caregivers using a questionnaire. Adverse events were evaluated by the investigators. RESULTS: Of 116 subjects enrolled in this study, 115 received treatment with the disposable pen and 109 completed the study. The mean age of the subjects was 9.4 years. Compared to the previous reusable device, the disposable pen was assessed as significantly easier to use (mean value 7.88, 95% confidence interval (CI) [7.45–8.30] on a numerical scale ranging from 0 (far less easy) to 10 (far easier)). Furthermore, the percentage of subjects who preferred the disposable pen to the previously used reusable device was 75.7% (95% CI [67.6%–83.8%]). The percentages of subjects who rated pain and discomfort at the injection site as “not at all” were higher after using the disposable pen compared to the reusable device. No specific safety concerns were identified. CONCLUSION: The disposable pen is easier to use than the reusable devices and is preferred by approximately 75% of patients receiving rhGH treatment. Moreover, the disposable pen is safe and acceptable. Therefore, it could be a good alternative to reusable devices. The disposable pen is expected to provide benefits to patients receiving rhGH treatment. CLINICALTRIALS.GOV IDENTIFIER: NCT03015909. |
format | Online Article Text |
id | pubmed-6929929 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-69299292020-01-06 Ease of Use, Preference, and Safety of the Recombinant Human Growth Hormone Disposable Pen Compared with the Reusable Device: A Multicenter, Single-Arm, Open-Label, Switch-Over, Prospective, Phase IV Trial Lee, Ji-Eun Kim, Se Young Yoo, Jae-Ho Hwang, Il Tae Lim, Jung Sub Yi, Kyung Hee Rhie, Young-Jun Lee, Gyung Min Nam, Hyo-Kyoung Chae, Hyun Wook Kim, Eun Young Cheon, Chong Kun Lee, Jieun Shim, Young Suk Lee, YuJin Kim, Eun Young Hwang, Jin Soon Patient Prefer Adherence Original Research PURPOSE: To assess the usability and safety of the disposable pen compared to those of reusable devices in patients receiving recombinant human growth hormone (rhGH) treatment. PATIENTS AND METHODS: This study was a multicenter, single-arm, open-label, switch-over, prospective, Phase IV trial. After screening, eligible patients who were previously treated with rhGH using a reusable device were enrolled to receive treatment with the disposable pen for 8 weeks. The ease of use, preference, and tolerability of the disposable pen compared to those of the reusable device were assessed by the subjects and/or their caregivers using a questionnaire. Adverse events were evaluated by the investigators. RESULTS: Of 116 subjects enrolled in this study, 115 received treatment with the disposable pen and 109 completed the study. The mean age of the subjects was 9.4 years. Compared to the previous reusable device, the disposable pen was assessed as significantly easier to use (mean value 7.88, 95% confidence interval (CI) [7.45–8.30] on a numerical scale ranging from 0 (far less easy) to 10 (far easier)). Furthermore, the percentage of subjects who preferred the disposable pen to the previously used reusable device was 75.7% (95% CI [67.6%–83.8%]). The percentages of subjects who rated pain and discomfort at the injection site as “not at all” were higher after using the disposable pen compared to the reusable device. No specific safety concerns were identified. CONCLUSION: The disposable pen is easier to use than the reusable devices and is preferred by approximately 75% of patients receiving rhGH treatment. Moreover, the disposable pen is safe and acceptable. Therefore, it could be a good alternative to reusable devices. The disposable pen is expected to provide benefits to patients receiving rhGH treatment. CLINICALTRIALS.GOV IDENTIFIER: NCT03015909. Dove 2019-12-20 /pmc/articles/PMC6929929/ /pubmed/31908426 http://dx.doi.org/10.2147/PPA.S229536 Text en © 2019 Lee et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Lee, Ji-Eun Kim, Se Young Yoo, Jae-Ho Hwang, Il Tae Lim, Jung Sub Yi, Kyung Hee Rhie, Young-Jun Lee, Gyung Min Nam, Hyo-Kyoung Chae, Hyun Wook Kim, Eun Young Cheon, Chong Kun Lee, Jieun Shim, Young Suk Lee, YuJin Kim, Eun Young Hwang, Jin Soon Ease of Use, Preference, and Safety of the Recombinant Human Growth Hormone Disposable Pen Compared with the Reusable Device: A Multicenter, Single-Arm, Open-Label, Switch-Over, Prospective, Phase IV Trial |
title | Ease of Use, Preference, and Safety of the Recombinant Human Growth Hormone Disposable Pen Compared with the Reusable Device: A Multicenter, Single-Arm, Open-Label, Switch-Over, Prospective, Phase IV Trial |
title_full | Ease of Use, Preference, and Safety of the Recombinant Human Growth Hormone Disposable Pen Compared with the Reusable Device: A Multicenter, Single-Arm, Open-Label, Switch-Over, Prospective, Phase IV Trial |
title_fullStr | Ease of Use, Preference, and Safety of the Recombinant Human Growth Hormone Disposable Pen Compared with the Reusable Device: A Multicenter, Single-Arm, Open-Label, Switch-Over, Prospective, Phase IV Trial |
title_full_unstemmed | Ease of Use, Preference, and Safety of the Recombinant Human Growth Hormone Disposable Pen Compared with the Reusable Device: A Multicenter, Single-Arm, Open-Label, Switch-Over, Prospective, Phase IV Trial |
title_short | Ease of Use, Preference, and Safety of the Recombinant Human Growth Hormone Disposable Pen Compared with the Reusable Device: A Multicenter, Single-Arm, Open-Label, Switch-Over, Prospective, Phase IV Trial |
title_sort | ease of use, preference, and safety of the recombinant human growth hormone disposable pen compared with the reusable device: a multicenter, single-arm, open-label, switch-over, prospective, phase iv trial |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6929929/ https://www.ncbi.nlm.nih.gov/pubmed/31908426 http://dx.doi.org/10.2147/PPA.S229536 |
work_keys_str_mv | AT leejieun easeofusepreferenceandsafetyoftherecombinanthumangrowthhormonedisposablepencomparedwiththereusabledeviceamulticentersinglearmopenlabelswitchoverprospectivephaseivtrial AT kimseyoung easeofusepreferenceandsafetyoftherecombinanthumangrowthhormonedisposablepencomparedwiththereusabledeviceamulticentersinglearmopenlabelswitchoverprospectivephaseivtrial AT yoojaeho easeofusepreferenceandsafetyoftherecombinanthumangrowthhormonedisposablepencomparedwiththereusabledeviceamulticentersinglearmopenlabelswitchoverprospectivephaseivtrial AT hwangiltae easeofusepreferenceandsafetyoftherecombinanthumangrowthhormonedisposablepencomparedwiththereusabledeviceamulticentersinglearmopenlabelswitchoverprospectivephaseivtrial AT limjungsub easeofusepreferenceandsafetyoftherecombinanthumangrowthhormonedisposablepencomparedwiththereusabledeviceamulticentersinglearmopenlabelswitchoverprospectivephaseivtrial AT yikyunghee easeofusepreferenceandsafetyoftherecombinanthumangrowthhormonedisposablepencomparedwiththereusabledeviceamulticentersinglearmopenlabelswitchoverprospectivephaseivtrial AT rhieyoungjun easeofusepreferenceandsafetyoftherecombinanthumangrowthhormonedisposablepencomparedwiththereusabledeviceamulticentersinglearmopenlabelswitchoverprospectivephaseivtrial AT leegyungmin easeofusepreferenceandsafetyoftherecombinanthumangrowthhormonedisposablepencomparedwiththereusabledeviceamulticentersinglearmopenlabelswitchoverprospectivephaseivtrial AT namhyokyoung easeofusepreferenceandsafetyoftherecombinanthumangrowthhormonedisposablepencomparedwiththereusabledeviceamulticentersinglearmopenlabelswitchoverprospectivephaseivtrial AT chaehyunwook easeofusepreferenceandsafetyoftherecombinanthumangrowthhormonedisposablepencomparedwiththereusabledeviceamulticentersinglearmopenlabelswitchoverprospectivephaseivtrial AT kimeunyoung easeofusepreferenceandsafetyoftherecombinanthumangrowthhormonedisposablepencomparedwiththereusabledeviceamulticentersinglearmopenlabelswitchoverprospectivephaseivtrial AT cheonchongkun easeofusepreferenceandsafetyoftherecombinanthumangrowthhormonedisposablepencomparedwiththereusabledeviceamulticentersinglearmopenlabelswitchoverprospectivephaseivtrial AT leejieun easeofusepreferenceandsafetyoftherecombinanthumangrowthhormonedisposablepencomparedwiththereusabledeviceamulticentersinglearmopenlabelswitchoverprospectivephaseivtrial AT shimyoungsuk easeofusepreferenceandsafetyoftherecombinanthumangrowthhormonedisposablepencomparedwiththereusabledeviceamulticentersinglearmopenlabelswitchoverprospectivephaseivtrial AT leeyujin easeofusepreferenceandsafetyoftherecombinanthumangrowthhormonedisposablepencomparedwiththereusabledeviceamulticentersinglearmopenlabelswitchoverprospectivephaseivtrial AT kimeunyoung easeofusepreferenceandsafetyoftherecombinanthumangrowthhormonedisposablepencomparedwiththereusabledeviceamulticentersinglearmopenlabelswitchoverprospectivephaseivtrial AT hwangjinsoon easeofusepreferenceandsafetyoftherecombinanthumangrowthhormonedisposablepencomparedwiththereusabledeviceamulticentersinglearmopenlabelswitchoverprospectivephaseivtrial |